All Blogs
May 09, 2025
ENHERTU’s Rapid Rise: How the HER2-Targeting ADC Is Redefining Cancer Treatment with Back-to-Back Label Expansions
ENHERTU, a next-generation antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo/ AstraZeneca since March 2019, except in Japan, where Daiichi Sankyo maintains exclusive rights. It is worth noting that recently, in November 2024, Daiichi Sankyo and AstraZeneca were awarded the Galien Foundation 2024 Pri...
Read More...
Dec 30, 2022
Need of the Hour: Enhanced Strategies for PD-LID Treatment and Management
Parkinson’s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain’s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a...
Read More...
Dec 29, 2022
PAVmed-Novosound’s Partnership; J&J Acquires Abiomed; Approval to Sysmex’s Assay Kit to Identify Amyloid Beta (Aβ) Accumulation; SI-BONE Announced FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite Implant System; EOFlow’s Wearable Insulin Pump ‘EOPatch’; Icecure’s ProSense System, a Cryoablation Therapy
PAVmed Entered into a Partnership with Novosound for Ultrasound Imaging Technology On December 22, 2022, PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that the company has entered into a partnership with...
Read More...
Dec 28, 2022
How is Active Implantable Medical Devices Market Evolving?
Over the past few years, the growth and development in electronics, micro and nano-fabrication, and wireless technology have significantly enhanced the quality and effectiveness of healthcare delivery systems, and treatment outcomes and led to various insights in the biological investigations through research and d...
Read More...
Dec 27, 2022
Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC
FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be...
Read More...
Dec 26, 2022
Limbal Stem Cell Deficiency (LSCD): A Multifactorial Disease with Challenging Diagnosis and Treatment
Limbal Stem Cell Deficiency (LSCD) is a rare, progressive ocular surface disorder that results in conjunctivalization and neovascularization of the corneal surface. Ocular discomfort, reduced visual acuity, and photophobia are all symptoms of LSCD, which can be brought on by severe ocular surface illness. ...
Read More...
Dec 22, 2022
Medtronic’s Hugo Robotic-Assisted Surgery System Trial; Insightec’s Pivotal LIBERATE Clinical Trial; FDA Granted EMA for Thermo Fisher Scientific’s Monkeypox Test; Life Spine’s Trulift Lateral Expandable Spacer System & Lateral Pate System; Fujifilm & Inspirata Announces Asset Purchase Agreement; Abbott Launched SCS System for Chronic Pain
Medtronic Announced First Patient Enrolment for Hugo™ Robotic-Assisted Surgery System in US Clinical Trial On December 15, 2022, Medtronic, a global healthcare technology leader, announced that the first patient was enrolled in the Expand URO US clinical trial for the Hugo™ robotic-assisted surgery...
Read More...
Dec 21, 2022
How is Nuclear Medicine Bringing Groundbreaking Transformation in the Healthcare Industry?
Nuclear Medicine is an integral part of today’s healthcare delivery system and provides an immense benefit to patient care. Over the past four-five decades, there has been intense growth in the Nuclear Medicine Market owing to the development of various radionuclide and radio-labeled compounds and equipment. The ap...
Read More...
Dec 20, 2022
Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result
AbbVie Secures Fourth FDA Approval for Vraylar AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. According to AbbVie, the approval makes Vraylar (cariprazi...
Read More...
Dec 23, 2022
Awaited Approval for New Therapies for Head and Neck Cancer Treatment – A Race Against Time!
Head and neck cancer is a complex indication and is common among men and people over 50 and accounts for 3–5% of all cancers in the US. As per the assessment done by DelveInsight, there were approximately 158K incident cases of head and neck cancer in the 7MM in 2021. Among the EU5 countries, Germany had the highes...
Read More...